Xiangyu Ling
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
GALNT7 promotes hepatocellular carcinoma progression by activating the PI3K/AKT signaling pathway via O-glycosylation of MUC13.
Journal: Acta biochimica et biophysica Sinica
Published: December 24, 2025
Hypoxia-induced RCOR2 promotes macrophage M2 polarization and CD8+ T-cell exhaustion by enhancing LIF transcription in hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: September 15, 2025
The HKDC1-ASS1-ACSBG2 axis reprograms lipid metabolism to drive therapeutic resistance in hepatocellular carcinoma.
Journal: Journal of translational medicine
Published: August 14, 2025
The deficiency of ALKBH5 promotes lenvatinib resistance and CD8+ T cell exhaustion via accumulation of the cholesterol metabolite 27HC in hepatocellular carcinoma.
Journal: Cancer letters
Published: June 05, 2025
TTC36-Mediated Tumor Suppression via YBX3/SPRED1 Axis Paradoxically Reduces Sorafenib Sensitivity in Hepatocellular Carcinoma.
Journal: International journal of biological sciences
Published: April 14, 2025
LRP11 facilitates lipid metabolism and malignancy in hepatocellular carcinoma by stabilizing RACK1 through USP5 regulation.
Journal: Molecular medicine (Cambridge, Mass.)
Published: October 21, 2024
Predicting hepatocellular carcinoma outcomes and immune therapy response with ATP-dependent chromatin remodeling-related genes, highlighting MORF4L1 as a promising target.
Journal: Cancer cell international
Published: July 04, 2024
Circ_0007386 Promotes the Progression of Hepatocellular Carcinoma Through the miR-507/ CCNT2 Axis.
Journal: Journal of hepatocellular carcinoma
Published: January 14, 2024
Showing 1-9 of 9
Last Updated: 09/26/2026